Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine

European Journal of Health Economics

Volumn 3, Issue 3, 2002, Pages 166-172

  Herold, M ^a   Hieke, Klaus ^b  

^a HELIOS KLINIKUM ERFURT   (Germany)

^b NEOS Health   (Switzerland)

Author keywords

Adverse events; CHOP regimen; COP regimen; Cost analysis; Fludarabine; Non Hodgkin's lymphoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; COST EFFECTIVENESS ANALYSIS; ENVIRONMENTAL FACTOR; FEVER; HUMAN; INFECTION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0036970061     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-002-0112-y     Document Type: Article

References (32)

1. Cartwright RA, McNally RJQ, Staines A (1994) The increasing incidence of non-Hodgkin's lymphoma (NHL): the possible role of sunlight. Leuk Lymphoma 14:387-394
2. Devesa SS, Fears T (1992) Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 52 [Suppl 2]:5432-5440
3. Weisenberger DD (1992) Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 5 [Suppl 1]:19-24
4. Parkin D, Whelan S, Ferlay J, Raymond L, Young J (eds) (1997) Cancer incidence in five continents,vol VII. Lyon: IARC, no 143
5. Morgan G, Vornanen M, Puitinen J, Naukkarinen A, Brincker H, Olsen J, Coeburgh JW, Vrints LW, Clayden D, McNally R, Jack A, Carli PM, Petrella T, Tomino R, D'Lollo S, Barchielli A, Cartwright R (1997) Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Biomed Study Group. Ann Oncol 8 [Suppl 2]:49-54
6. Black RJ, Bray F, Ferlay J, Parkin DM (1997) Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33:1075-1107
7. Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918
8. Hiddemann W, Unterhalt M (1998) Stand und Perspektiven in der Therapie follikulärer Keimzentrumslymphome. Dtsch Arztebl 95:50
9. McLaughlin P, Robertson LE, Keating MJ (1996) Fludarabine phosphate in lymphoma: an important new therapeutic agent. Cancer Treat Res 85:3-14
10. Tedeschi A, Montillo M, Capelli D, et al (1996) Phase I study of the combination of fludarabine, idarubicin and dexamethasone in low grade lymphoma (abstract). Blood 88 [Suppl 1]:195b
11. Zinzani PL, Bendandi M, Gherlinzoni F, Merla E, Gozzetti A, Tura S (1996) FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low grade non-Hodgkin's lymphoma. Haematologica 81:168-171
12. Pott C, Unterhalt M, Sandford D, et al (1994) Fludarabine in combination with mitoxantrone and dexamethasone in relapsed and refractory low-grade non-Hodgkin's lymphoma (abstract). Onkologie 17 [Suppl 2]:114
13. McLaughlin P, Hagemeister FB, Romaguera JE, et al (1996) Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268
14. Zinzani PL, Bendandi M, Tura S (1995) FMP regimen (fludarabine mitoxantrone, prednisone) as therapy in recurrent low grade lymphoma. Eur J Haematol 55:262-266
15. Schilder R (1999) Rituximab immunotherapy. Cancer Biother Radiopharm 14:237-240
16. Hainsworth JD, Burris 3rd HA, Morrissey LH, et al (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052-3056
17. Davis TA, Maloney DG, Grillo-Lopez AJ, et al (2000) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 6:2644-2652
18. Czuczman M, Grillo-Lopez AJ, White CA, et al (2001) Progression-free survival after six years (median) follow-up of the first clinical trial of rituximab/CHOP chemoimmunotherapy. Blood 98 [Suppl 1]:601a
19. Tsimberidou AM, McLaughlin P, Younes A, et al (2000) Randomized comparison of fludarabine/novantrone/dexamethasone versus CHOP-BLEO/ESHAP/NOPP (alternating triple therapy) in patients with stage IV indolent lymphoma. Blood 96 [Suppl 1]:508a
20. Kimby E, Geisler C, Hagberg H, et al (2000) Rituximab (MabThera) as single agent and in combination with interferon-alpha-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. A randomized phase II study M 39035. Blood 96 [Suppl 1]:577a
21. Fisher RI, Gaynor ER, Dahlberg S, et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
22. Miller TP, Dahlberg S, Cassady R, et al (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26
23. Sweetenham J, Hieke K, Kerrigan M, Howard P, Smartt PFM, McIntyre AM (1999) Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the UK. Br J Haematol 106:47-54
24. Hochster HS, Kim K, Green MD, et al (1992) Activity of fludarabine in previously treated non-Hodgkin's lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32
25. Dranitsaris G, Altmayer C, Quirt I (1997) Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma. Pharmacoeconomics 11:566-577
26. Jacobs, Bachynsky (1997) Working Paper Series. Institute of Pharmacoeconomics, pp 97-95
27. Dranitsaris G, Phillips P, Rotstein C, et al (1998) Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients. Pharmacoeconomics 13:509-518
28. Moncton NB (1996) Total pricing systems 1998 [fludarabine]; Ontario Ministry of Health. Drug benefit formulary/comparative drug index, no 35 (update August 27, 1997). Toronto: PPS Pharma Publications
29. Kimby E, Björkholm M, Gahrton G, et al (1994) Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 5:S67-S71
30. Whelan JS, Davis CL, Rule S, et al (1991) Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64:120-123
31. Pigaditou A, Rohatiner AZS, Whelan JS, et al (1993) Fludarabine in low grade lymphoma. Semin Oncol 20:24-27
32. Falkson CI (1996) Fludarabine: a phase II clinical trial in patients with previously low-grade lymphoma. Am J Clin Oncol 19:268-270